This semi-annual, multi-client, oncology trends study includes three oncology market research arms surveying approximately 100 payers, 100 oncologists, and 100 oncology practice managers, twice annually. Started in 2006, the survey explores a wide range of managed care oncology management trends and issues, including physician reimbursement management, prior authorization, patient cost-sharing, specialty pharmacy, site-of-care dynamics, practice economics, and clinical guidelines.
What actions can you take?
- Inform strategic decisions related to access and reimbursement of oncologics
- Leverage information collectively requested by marketers from major oncology companies
- Make access strategy recommendations with robust, market-representative, quantitative research and analysis
- Develop timely strategies with reports that evolve based on your needs
- Enhance oncology product marketing effectiveness and efficiency
- Tailor marketing strategies and tactics through better understanding of how oncologists work with practice managers to respond to payer policies
- Identify sales leverage points through insights into oncologist awareness of and sensitivity to payer policies
What insights are provided?
- Longitudinal data on access drivers and payers’ expectations for the future
- Perspectives of payers, physicians, and oncology practice managers relative to utilization management techniques and cost-sharing benefit design
- Impact of payer management strategies on practice finance, including the health care reform foundation
- Perceptions and prevalence of emerging access tools, such as companion diagnostics and clinical pathways
With the Managed Care Oncology Index, you can subscribe to a basic or live subscription.
|Two semi-annual editions||Check||Check|
|Four formal presentations of findings||Check|
|Two formal presentation of findings||Check|
|Attendance at one follow-up web conference with survey panelists per edition||Check||Check|
|Up to three customized reports/data cuts per edition (each containing up to five unique data cuts)||Check|
|Access to the research team for follow-up questions, data clarification, or additional insight (up to ten hours of telephonic support per edition)||Check|